These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 29905976)

  • 1. Pharmacokinetics, Safety, and Tolerability of Rolapitant Administered Intravenously Following Single Ascending and Multiple Ascending Doses in Healthy Subjects.
    Wang X; Zhang ZY; Wang J; Powers D; Arora S; Lu S; Kansra V
    Clin Pharmacol Drug Dev; 2019 Feb; 8(2):160-171. PubMed ID: 29905976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioequivalence of Intravenous and Oral Rolapitant: Results From a Randomized, Open-Label Pivotal Study.
    Wang X; Zhang ZY; Powers D; Wang J; Lu S; Arora S; Hughes L; Christensen J; Kansra V
    J Clin Pharmacol; 2017 Dec; 57(12):1600-1606. PubMed ID: 28906561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Rolapitant Administered Intravenously or Orally on the Pharmacokinetics of Digoxin (P-glycoprotein Substrate) and Sulfasalazine (Breast Cancer Resistance Protein Substrate) in Healthy Volunteers.
    Wang X; Zhang ZY; Arora S; Hughes L; Wang J; Powers D; Christensen J; Lu S; Kansra V
    J Clin Pharmacol; 2018 Feb; 58(2):202-211. PubMed ID: 28906558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of Rolapitant in Patients With Mild to Moderate Hepatic Impairment.
    Wang J; Wang X; Zhang ZY; Arora S; Lu S; Kansra V
    J Clin Pharmacol; 2018 May; 58(5):686-693. PubMed ID: 29329482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Open-Label, Randomized, Pivotal Bioequivalence Study of Oral Rolapitant.
    Zhang ZY; Wang J; Arora S; Lu S; Powers D; Kansra V; Wang X
    Clin Pharmacol Drug Dev; 2019 Feb; 8(2):152-159. PubMed ID: 30624856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials.
    Rapoport BL; Chasen MR; Gridelli C; Urban L; Modiano MR; Schnadig ID; Poma A; Arora S; Kansra V; Schwartzberg LS; Navari RM
    Lancet Oncol; 2015 Sep; 16(9):1079-1089. PubMed ID: 26272769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
    Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
    Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic Interactions of Rolapitant With Cytochrome P450 3A Substrates in Healthy Subjects.
    Wang X; Wang J; Arora S; Hughes L; Christensen J; Lu S; Zhang ZY
    J Clin Pharmacol; 2019 Apr; 59(4):488-499. PubMed ID: 30422319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absorption, metabolism, and excretion of the antiemetic rolapitant, a selective neurokinin-1 receptor antagonist, in healthy male subjects.
    Zhang ZY; Wang J; Kansra V; Wang X
    Invest New Drugs; 2019 Feb; 37(1):139-146. PubMed ID: 30032410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial.
    Schwartzberg LS; Modiano MR; Rapoport BL; Chasen MR; Gridelli C; Urban L; Poma A; Arora S; Navari RM; Schnadig ID
    Lancet Oncol; 2015 Sep; 16(9):1071-1078. PubMed ID: 26272768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics of Rolapitant in Patients With Chemotherapy-Induced Nausea and Vomiting.
    Wang X; Wang J; Zhang ZY; Kansra V
    Clin Pharmacol Drug Dev; 2019 Oct; 8(7):850-860. PubMed ID: 31418538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).
    Rapoport B; Chua D; Poma A; Arora S; Wang Y; Fein LE
    Support Care Cancer; 2015 Nov; 23(11):3281-8. PubMed ID: 25940030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects.
    Wang J; Zhang ZY; Lu S; Powers D; Kansra V; Wang X
    Support Care Cancer; 2019 Mar; 27(3):819-827. PubMed ID: 30084103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy.
    Navari RM
    Expert Opin Drug Saf; 2019 Dec; 18(12):1127-1132. PubMed ID: 31622113
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy.
    Hesketh PJ; Schnadig ID; Schwartzberg LS; Modiano MR; Jordan K; Arora S; Powers D; Aapro M
    Cancer; 2016 Aug; 122(15):2418-25. PubMed ID: 27176138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rolapitant: An NK-1 Receptor Antagonist for the Prevention of Chemotherapy- Induced Nausea and Vomiting.
    Rapoport BL
    Rev Recent Clin Trials; 2017; 12(3):193-201. PubMed ID: 28393710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rolapitant: first global approval.
    Syed YY
    Drugs; 2015 Nov; 75(16):1941-5. PubMed ID: 26467681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial Spiroindolone KAE609 (Cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers.
    Leong FJ; Li R; Jain JP; Lefèvre G; Magnusson B; Diagana TT; Pertel P
    Antimicrob Agents Chemother; 2014 Oct; 58(10):6209-14. PubMed ID: 25114127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infusion reactions following administration of intravenous rolapitant at an academic medical center.
    Cass AS; Odinet JS; Valgus JM; Crona DJ
    J Oncol Pharm Pract; 2019 Oct; 25(7):1776-1783. PubMed ID: 30348072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase 1 Assessment of the QT Interval in Healthy Adults Following Exposure to Rolapitant, a Cancer Supportive Care Antiemetic.
    Wang X; Zhang ZY; Wang J; Kansra V
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):603-611. PubMed ID: 30256537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.